Findings show metabolic dysfunction-associated fatty liver disease raises colorectal cancer risk in specific age groups, suggesting enhanced screening is needed.
MAFLD was independently associated with an increased risk of ACN; however, this association differed according to age and MAFLD subtype. Patients with MAFLD, especially those with high fibrotic burden, underlying diabetes, or aged less than or equal to 50 years, may benefit from appropriate colorectal cancer screening.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: